Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells

Rosa L. Vincent; Fangda Li; Edward R. Ballister; Nicholas Arpaia; Tal Danino

doi:10.3791/65887

JoVE Journal
Bioengineering

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Bioengineering

Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells

小鼠嵌合抗原受体（CAR）-T细胞的高效生成

Full Text

5,199 Views

06:22 min

February 2, 2024

DOI: 10.3791/65887-v

Rosa L. Vincent¹, Fangda Li², Edward R. Ballister¹, Nicholas Arpaia^2,3, Tal Danino^1,3,4

¹Department of Biomedical Engineering,Columbia University, ²Department of Microbiology & Immunology, Vagelos College of Physicians and Surgeons,Columbia University, ³Herbert Irving Comprehensive Cancer Center,Columbia University, ⁴Data Science Institute,Columbia University

Please note that some of the translations on this page are AI generated. Click here for the English version.

Overview

This protocol streamlines retroviral vector production and murine T cell transduction, facilitating the efficient generation of mouse CAR-T cells. The study focuses on the integration of engineered bacteria and CAR-T cells for solid tumor treatment in syngeneic models.

Key Study Components

Area of Science

Neuroscience
Immunology
Oncology

Background

CAR-T cell therapy is a promising approach for cancer treatment.
Murine models are essential for studying CAR-T cell efficacy.
Standardized protocols for generating murine CAR-T cells are lacking.
Transduction of murine T-cells is challenging with traditional methods.

Purpose of Study

To develop a streamlined protocol for murine CAR-T cell production.
To enable effective study of CAR-T cells in syngeneic tumor models.
To evaluate the activity of new CAR technologies in a complete immune system context.

Methods Used

Preparation of reduced serum medium for transduction.
Dilution of media with transfection reagent.
Application of the protocol to murine T cells.
Evaluation of CAR-T cell functionality in syngeneic models.

Main Results

The protocol successfully enhances murine T cell transduction efficiency.
Generated CAR-T cells exhibit improved functionality in tumor models.
Standardization allows for reproducibility in research.
Facilitates further exploration of CAR technologies.

Conclusions

This protocol provides a reliable method for generating murine CAR-T cells.
It supports the study of CAR-T cell interactions within the immune system.
Future research can build on this foundation to enhance cancer therapies.

Frequently Asked Questions

What are CAR-T cells?

CAR-T cells are genetically engineered T cells designed to target and kill cancer cells.

Why are murine models used in this research?

Murine models provide a relevant biological context to study immune responses and cancer therapies.

What challenges exist in murine T cell transduction?

Murine T cells are often difficult to transduce and culture using traditional methods.

How does this protocol improve CAR-T cell production?

The protocol streamlines the production process, enhancing transduction efficiency and reproducibility.

What implications does this research have for cancer treatment?

It paves the way for improved CAR-T cell therapies and better understanding of their mechanisms in solid tumors.

Can this protocol be adapted for other types of cells?

While designed for murine T cells, the principles may be applicable to other cell types with modifications.

该方案简化了逆转录病毒载体的产生和小鼠T细胞的转导，促进了小鼠CAR-T细胞的高效生成。

我们的研究探索了工程细菌和CAR T细胞在实体瘤治疗中的有效组合。对我们来说，使用卵巢癌的同基因模型研究这两种细胞疗法如何在完整免疫系统的背景下发挥作用是很重要的。由于缺乏用于生成小鼠CAR T细胞的标准化方案，研究CAR T细胞在同基因肿瘤模型中的功能受到限制。

使用传统方法在体外培养中转导小鼠T细胞特别困难。我们开发了该协议以简化小鼠CAR T细胞的生产，以便在同基因模型中进行研究，从而为评估新CAR技术的活性提供重要背景。

View the full transcript and gain access to thousands of scientific videos

Explore More Videos

本月在JoVE第204期